Trials / Recruiting
RecruitingNCT06672185
ARC101 in Advanced Solid Tumors
A Phase 1 Study of ARC101 in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Third Arc Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARC101 | ARC101 will be administered according to an assigned dose schedule. |
Timeline
- Start date
- 2025-02-05
- Primary completion
- 2028-05-01
- Completion
- 2028-08-01
- First posted
- 2024-11-04
- Last updated
- 2026-04-03
Locations
12 sites across 4 countries: United States, Australia, Canada, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06672185. Inclusion in this directory is not an endorsement.